Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.57 |
| ▸ | LIPE | Q05469 | 11/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042055 | 0.91 | PPARG (0.63) | PPARGLIPELMNAPPARAPPARD | |
| SCHEMBL7036261 | 0.83 | PPARG (0.82) | PPARGLMNAPPARAKMT2A | |
| SCHEMBL7040735 | 0.79 | PPARG (0.79) | PPARGLMNAPPARA | |
| SCHEMBL7036241 | 0.79 | PPARG (0.80) | PPARGLMNAPPARA | |
| SCHEMBL7038602 | 0.75 | PPARG (0.54) | PPARGLMNAPPARAKMT2APPARD | |
| Lithium SCHEMBL7039319 | 0.74 | PPARG (0.53) | PPARGLMNAPPARAKMT2APPARD | |
| SCHEMBL7039317 | 0.74 | PPARG (0.53) | PPARGLMNAPPARAKMT2APPARD | |
| SCHEMBL7035602 | 0.74 | PPARG (0.56) | PPARGLMNAPPARAKMT2A | |
| SCHEMBL7039776 | 0.73 | PPARG (0.85) | PPARGLMNAPPARAKMT2A | |
| SCHEMBL7039770 | 0.73 | PPARG (0.85) | PPARGLMNAPPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885LIPE 263/4885LMNA 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.